abraxane,paclitaxel,bevacizumab
roche,amgen
['strategic-1', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'sequence,(-consequence)']
phiii strategic-1 in #1l ras/braf wt #mcrc (80% l-sided) sequence of (a) folfiri-cmab-&gt;folfox-bev vs (b) optimox-bev-&gt;folfiri-bev-&gt;anti-egfr mab shows no sig diff in duration of disease control (primary endpt) and os w/either seq (numerically higher w/arm a) #asco22 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope